It's been a month, and there's basically no news on the atypical antipsychotic front. Vanda still has no sales force for iloperidone, Wyeth still has no chance with bifeprunox, and Seroquel still dominates the marketplace. The only thing new is that Abilify is making a foray into the PCP arena now that they have the adjunctive depression label. Risperdal and Zyprexa continue to lose share. Clearly the big event or perhaps non-event of 2008 will be generic risperidone, and I don't think anyone knows how that will play out.
Tuesday, February 12, 2008
Subscribe to:
Post Comments (Atom)
2 comments:
With reference to the Abilify labeling for depression, Health Care Renewal recently carried detailed case studies of the deceptive methods used to promote off-label atypical antipsychotic drug use for depression. These case studies illustrate the corruption of even first-tier medical journals in service of marketing. Academic key opinion leaders work hand in glove with the corporations. The HCR posting for 16 January 2008 is: http://hcrenewal.blogspot.com/2008/01/antipsychotic-drugs-for-depression.html A companion case study of corruption in continuing medical education appeared on 22 January (http://hcrenewal.blogspot.com/2008/01/variations-on-theme-of-sleaze.html). The principal KOL in these cases, a member of the Institute of Medicine no less, has a long history of ethical controversy. The new Abilify road show is well under way, no expense spared.
Thanks for the comment. It'll be interesting to see how the on label promotion heats up once Seroquel gets its depression indication.
Post a Comment